How Does Tirzepatide Work? GIP and GLP-1 Explained

Tirzepatide is a once-weekly injection that activates two gut hormone receptors at once: GIP and GLP-1. Together they lower appetite and calorie intake, slow stomach emptying for a time, boost insulin release only when blood sugar is elevated, and improve how well the body responds to insulin. In the 72-week SURMOUNT-1 trial of 2,539 adults without diabetes, average weight loss was 15.0% to 20.9% depending on dose, compared with 3.1% on placebo. The drug carries a boxed warning about thyroid C-cell tumors seen in rats, and exactly how much the GIP half contributes in humans is still not settled.

Where tirzepatide stands with the FDA

As of September 2026, tirzepatide is an FDA-approved prescription drug sold in the United States as two products made by the same manufacturer, Eli Lilly. The active ingredient is identical. What differs is the approved use.

• The FDA-approved tirzepatide product for type 2 diabetes is approved to improve blood sugar control, alongside diet and exercise, in adults and in children 10 years and older with type 2 diabetes. In August 2026 the FDA added a second use to its label: reducing the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for them.
• The FDA-approved tirzepatide product for weight management was approved on November 8, 2023 to reduce excess body weight and maintain that reduction long term in adults with obesity, or with overweight plus at least one weight-related condition, in combination with a reduced-calorie diet and more physical activity. On December 20, 2024 the FDA added treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The cardiovascular indication rests on SURPASS-CVOT, which assigned 13,299 adults with type 2 diabetes and established cardiovascular disease to tirzepatide or dulaglutide, a GLP-1 drug already shown to reduce cardiovascular events. Over a median follow-up of about four years, a major event occurred in 12.2% on tirzepatide and 13.1% on dulaglutide (hazard ratio 0.92). That met the test for being no worse than dulaglutide but not the test for being better. The FDA label for the weight-management tirzepatide product carries no cardiovascular indication as of August 2026.

Neither label allows tirzepatide to be combined with another tirzepatide product or with any GLP-1 receptor agonist. The weight-management tirzepatide product has not been shown to be safe or effective in children.

Tirzepatide was on the FDA drug shortage list from 2022 until the agency declared the shortage resolved on December 19, 2024, which ended the basis for routine compounding. Compounded tirzepatide is not FDA approved. More on that further down.

GIP and GLP-1: the two hormones tirzepatide imitates

GIP and GLP-1 belong to a family called incretins: hormones your intestine releases when you eat. Their shared job is to tell the pancreas that food is arriving so it can release insulin in proportion to the meal. Reviews of incretin biology describe the two together as responsible for the bulk of this meal-triggered insulin boost, known as the incretin effect.

What GLP-1 does

GLP-1 (glucagon-like peptide-1) is released by L cells in the gut lining. It is the better understood of the two, and the first drug that imitates it was approved for type 2 diabetes in 2005. Natural GLP-1 and GIP are both broken down in the body by an enzyme called DPP-4, so a drug that imitates them has to be engineered to resist that and to last. GLP-1's main actions are:

• Insulin, on demand. It increases insulin release when blood sugar is elevated and largely stops doing so when sugar is normal. This is why drugs in this family rarely cause low blood sugar on their own.
• Less glucagon. It suppresses glucagon, the hormone that tells the liver to release stored sugar, when blood sugar is high.
• Slower stomach emptying. Food leaves the stomach more slowly, which blunts the sugar spike after a meal and adds to the feeling of fullness.
• Less appetite. GLP-1 acts in parts of the brain that control appetite and food intake. The FDA label for the weight-management tirzepatide product describes GLP-1 as a physiological regulator of appetite and caloric intake. Reviews call the human evidence for reduced appetite and calorie intake robust.

If you want the single-hormone story in more depth, see how GLP-1 weight loss injections work.

What GIP does

GIP (glucose-dependent insulinotropic polypeptide) is released by K cells in the gut. Like GLP-1, it prompts the pancreas to release insulin when blood sugar rises. Beyond that, it behaves differently, and in some ways it is the more puzzling hormone.

• Glucagon goes the other way. GIP can stimulate glucagon rather than suppress it, depending on the blood sugar level.
• Appetite in humans: unproven. A 2022 review by two leading incretin researchers, Michael Nauck and David D'Alessio, states the key caveat plainly: GIP reduces food intake and body weight in rodents, but these effects have not been demonstrated in humans. In one human infusion study they cite, adding GIP to GLP-1 produced less appetite suppression than GLP-1 alone, not more.

There is a second complication. In people with type 2 diabetes, natural GIP has a much weaker effect on insulin release than it does in healthy people, while GLP-1's effect is largely preserved. For years that made GIP look like a poor drug target. Tirzepatide's results have forced a rethink.

How the tirzepatide molecule is built

Tirzepatide is a single synthetic peptide (a short chain of amino acids), 39 amino acids long. It is one molecule that fits both receptors, not a mixture of two drugs. Its sequence is based on natural GIP, with changes that let it also activate the GLP-1 receptor.

Attached to the chain is a 20-carbon fatty acid. This tail lets the molecule cling to albumin, the most abundant protein in your blood. The label reports that tirzepatide is 99% bound to albumin, which shields it from rapid breakdown and clearance. The result is an elimination half-life of roughly 5 to 6 days, which is what makes once-weekly dosing possible.

After an injection under the skin, blood levels peak at a median of 24 hours (range 8 to 72 hours), about 80% of the dose reaches the bloodstream, and levels settle into a steady state after about 4 weeks at a given dose. No dose adjustment is recommended for kidney or liver impairment.

An imbalanced agonist

An agonist is a molecule that switches a receptor on. Tirzepatide does not switch its two receptors on equally. Laboratory work published in JCI Insight in 2020, done in cell systems and isolated pancreatic islets by the manufacturer's scientists with academic collaborators, found that at clinically effective doses tirzepatide engages the GIP receptor to a greater degree than the GLP-1 receptor. At the GIP receptor it mimics the natural hormone. A 2022 review adds that its binding and effects at the GLP-1 receptor are weaker than those of natural GLP-1.

The same study found that tirzepatide is a biased agonist at the GLP-1 receptor: it favors one signaling route inside the cell (generation of a messenger called cAMP) over another (recruitment of a protein called beta-arrestin), and it is less prone to pulling the receptor off the cell surface. The authors suggested this could enhance insulin release. This is cell-level evidence, a plausible explanation and not a proven one in patients.

Why two receptors may work better than one

Head-to-head human data show tirzepatide outperforming a GLP-1-only drug on blood sugar and weight. Why it does so is less certain than marketing copy tends to suggest. Here is what each line of evidence actually supports. A full comparison of outcomes is in tirzepatide versus semaglutide.

Appetite and calorie intake

The FDA label for the weight-management tirzepatide product states that tirzepatide decreases calorie intake, likely by affecting appetite. It notes that both receptors are found in brain areas involved in appetite regulation, that animal studies show tirzepatide reaching and activating neurons there, and that nonclinical (animal and laboratory) studies suggest adding GIP may further contribute to regulating food intake.

The most direct human test is a 28-week randomized, double-blind study in 117 adults with type 2 diabetes, comparing tirzepatide 15 mg, semaglutide 1 mg, and placebo. Both drugs reduced appetite scores and calorie intake at a test lunch compared with placebo. Tirzepatide produced more weight loss and more fat loss than semaglutide, yet the appetite scores and calorie intake reductions did not differ between the two drugs.

The authors concluded that intake at a single test meal could not explain the difference in weight, and called for studies of 24-hour energy intake, fuel use, and energy expenditure. So part of tirzepatide's advantage is appetite, and part is something not yet pinned down. Note that semaglutide 1 mg is a diabetes dose, lower than the dose approved for weight management.

Nausea and tolerability

One hypothesis is that GIP makes the GLP-1 signal easier to tolerate, allowing more GLP-1 effect before nausea becomes limiting. In mice, rats, and musk shrews (a small mammal used in nausea research because it can vomit, which mice and rats cannot), activating the GIP receptor blocked vomiting and reduced sickness behaviors caused by GLP-1 drugs, while the reduction in food intake and weight was maintained.

That is animal evidence. In human trials, nausea remains the most common side effect of tirzepatide, reported by 25% to 29% of participants in the weight-management trials. Whether GIP activity spares people some nausea they would otherwise have had is not something those trials were designed to show.

The open question researchers still argue about

The Nauck and D'Alessio review lists what remains unshown: that GIP receptor activation reduces appetite in humans, and that it restores insulin release in people with type 2 diabetes. They also describe a hypothesis that seems backwards at first: constant stimulation may desensitize the GIP receptor, so a long-acting agonist could end up behaving partly like a blocker. Their summary is that more science is needed to reconcile the contrasting findings. The clearest human signal for a GIP contribution is in insulin sensitivity, covered next.

Effects on insulin and blood sugar

According to the prescribing information, tirzepatide stimulates insulin secretion in a glucose-dependent manner, reduces glucagon secretion, and increases insulin sensitivity. Insulin sensitivity means how strongly your muscle, fat, and liver cells respond to a given amount of insulin. Low sensitivity, called insulin resistance, is a central feature of type 2 diabetes and is common in obesity.

The clamp study

The label's statement rests on a hyperinsulinemic euglycemic clamp study. A clamp is the reference method for measuring insulin sensitivity: insulin is infused at a fixed rate, and researchers measure how much glucose must be infused to hold blood sugar steady. The more glucose needed, the more sensitive the body is.

The study, published in The Lancet Diabetes and Endocrinology in 2022, was a randomized, double-blind phase 1 trial that assigned 117 adults with type 2 diabetes on metformin to tirzepatide 15 mg, semaglutide 1 mg, or placebo for 28 weeks. Tirzepatide improved the combined measure of insulin secretion and insulin sensitivity far more than placebo and significantly more than semaglutide, and each component improved more with tirzepatide than with semaglutide.

The Nauck and D'Alessio review summarizes the sensitivity result as a rise of 65.7% with tirzepatide compared with 37.5% with semaglutide 1 mg. It also points out that, for the same amount of weight lost, insulin sensitivity improved more steeply with tirzepatide, which hints at an effect not explained by weight loss alone.

How much is the drug and how much is the weight loss

Weight loss improves insulin sensitivity by itself, so separating drug from weight is hard. In obese mice, a 2021 study in the Journal of Clinical Investigation found that tirzepatide still improved insulin sensitivity in animals engineered to lack the GLP-1 receptor, by increasing glucose uptake in white fat tissue, and a GIP-only agonist did the same. That points to the GIP receptor, but it is mouse data.

In humans without diabetes, a 2025 post hoc analysis of glucose tolerance tests from SURMOUNT-1 found that the gain in insulin sensitivity over 72 weeks was associated mostly with weight reduction and only partly with tirzepatide itself, while the gain in beta-cell function (how well the insulin-producing cells respond) was associated mostly with the treatment. Post hoc means designed after the trial ended, which is weaker evidence than a planned comparison.

Diabetes prevention over three years

The practical consequence showed up in the three-year extension of SURMOUNT-1, published in the New England Journal of Medicine. Among the 1,032 participants who had both obesity and prediabetes, 1.3% of those on tirzepatide were diagnosed with type 2 diabetes over 176 weeks, compared with 13.3% on placebo. After 17 weeks off treatment, the figures were 2.4% and 13.7%, a sign that some of the protection fades once the drug and the weight loss it sustains are withdrawn.

Low blood sugar

Because the insulin effect depends on glucose being elevated, hypoglycemia (low blood sugar) is uncommon when tirzepatide is used alone. In the trial of adults with type 2 diabetes and overweight or obesity, blood glucose below 54 mg/dL was reported in 4.2% on tirzepatide versus 1.3% on placebo, rising to 10.3% among those also taking a sulfonylurea. People who take insulin or a sulfonylurea need their prescriber to review those doses.

The dose-escalation schedule on the label

Tirzepatide is always started low and raised in steps. The label gives the reason directly: following the escalation reduces the risk of gastrointestinal side effects. The drug's effect on stomach emptying is largest after the first dose and diminishes with continued dosing, and the label reports that the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time.

The FDA label for the weight-management tirzepatide product sets out the schedule as follows. The starting dosage for every approved use is 2.5 mg injected under the skin once weekly for 4 weeks. The label is explicit that 2.5 mg is for starting treatment and is not an approved maintenance dosage. After 4 weeks, the dosage increases to 5 mg once weekly. From there it may be increased in 2.5 mg increments, after at least 4 weeks on the current dose.

The label does not print a week-by-week calendar, and the table repeats only its wording. If every step were taken at the 4-week minimum, 15 mg would be reached no earlier than week 21, but that is arithmetic from the minimum intervals, not a timetable the label sets. The words that matter are "at least" and "may". Four weeks is a minimum between steps, not a deadline, and not everyone goes to the top. The recommended maintenance dosages for weight reduction are 5 mg, 10 mg, or 15 mg once weekly. For obstructive sleep apnea they are 10 mg or 15 mg. The label tells prescribers to consider both response and tolerability when choosing a maintenance dose and, if a maintenance dose is not tolerated, to consider a lower one. In the trials, escalation took up to 20 weeks.

How fast the weight comes off: the SURMOUNT-1 time course

SURMOUNT-1 is the pivotal weight-management trial: a phase 3, double-blind, randomized trial that assigned 2,539 adults with a BMI of 30 or more, or 27 or more with a weight-related complication, to tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks. People with diabetes were excluded. Average starting weight was 104.8 kg (about 231 pounds). Everyone, including the placebo group, received counseling on a diet with a deficit of about 500 calories a day and at least 150 minutes of physical activity a week. Eli Lilly funded the trial.

These figures come from the prescribing information and count everyone who was randomized, whether or not they stayed on the drug. The step from 5 mg to 10 mg adds more than the step from 10 mg to 15 mg. And even at the top dose the spread is wide: more than half lost at least a fifth of their body weight, while roughly 1 in 11 did not reach 5%.

The first 12 weeks

During the first 12 weeks most people are still on the lower escalation doses, yet weight loss is usually already under way. A 2025 post hoc analysis looked at 1,545 SURMOUNT-1 participants on tirzepatide who took at least 75% of their doses. By week 12, 82% had already lost 5% or more of their starting weight. The authors called them early responders.

If the start is slow

The other 18% were labeled late responders. They were more often male (45% versus 30%) and started at a higher weight. A slow start did not mean failure: 70% of them had reached 5% weight loss by week 24 and 90% had by week 72, taking about 25 weeks on average to get there. Their final results were smaller, though: an average loss of 11.0% at week 72, against 22.5% for early responders.

When weight loss levels off

Weight does not fall forever. Another post hoc analysis, limited to participants who kept taking tirzepatide and lost at least 5%, defined a plateau as the point after which weight changed by less than 5% over every subsequent 12-week window. In SURMOUNT-1, the median time to plateau was about 24 weeks for participants who started in the overweight range, 26 weeks for class I obesity, and about 36 weeks for class II and class III obesity. By week 72, roughly 88% to 90% of those participants in every BMI category had plateaued. Higher doses, younger age, and female sex were associated with a longer period of continued loss. A plateau is an expected phase of treatment, not a sign the medication has stopped working, as the next two trials show.

What happens over the longer term

In the three-year SURMOUNT-1 extension in people with prediabetes, average weight loss at 176 weeks was 12.3% with 5 mg, 18.7% with 10 mg, and 19.7% with 15 mg, compared with 1.3% with placebo. The loss was largely held for as long as treatment continued.

SURMOUNT-4 tested what happens when treatment stops. After 36 weeks of tirzepatide at the highest tolerated dose (10 mg or 15 mg), 670 participants had lost an average of 20.9%. Half were then switched, without knowing it, to placebo. Over the next 52 weeks, those who stayed on tirzepatide lost a further 5.5%, while those on placebo regained 14.0%. In the end, 89.5% of the continued-treatment group had kept at least 80% of their initial loss, versus 16.6% of the placebo group. The biology of regain is similar across this drug class and is explained in what happens when you stop a GLP-1 medication.

Fat versus muscle

The label states that tirzepatide lowers body weight with greater fat mass loss than lean mass loss. In a body-scan (DXA) substudy of 160 SURMOUNT-1 participants, body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9% with tirzepatide over 72 weeks. About 75% of the weight lost was fat and 25% was lean mass, the same split seen with the smaller loss on placebo. Lean mass includes muscle but also water and organ tissue. The substudy was small and did not measure strength or physical function.

Obstructive sleep apnea: a newer approved use

Obstructive sleep apnea (OSA) happens when the upper airway repeatedly narrows or closes during sleep, causing pauses in breathing. Severity is measured by the apnea-hypopnea index (AHI): the number of breathing pauses and shallow-breathing episodes per hour of sleep. An AHI of 15 to under 30 is moderate, and 30 or more is severe. Excess weight is a major risk factor.

The approval rests on SURMOUNT-OSA, two 52-week phase 3 randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2024. Together they enrolled 469 adults with moderate to severe OSA and obesity, none with type 2 diabetes, averaging about 50 events per hour and a BMI of about 39. One trial enrolled people who could not or would not use positive airway pressure (PAP, the standard mask-based therapy). The other enrolled people who were using PAP. Tirzepatide was escalated to 10 mg or 15 mg.

In the trial of people not using PAP, AHI fell by 25.3 events per hour with tirzepatide and 5.3 with placebo, a drop of about 51% versus 3%. In the trial of people using PAP, it fell by 29.3 versus 5.5 events per hour, about 59% versus 3%. Remission, or mild OSA without symptoms, was reached by 42.2% versus 15.9% in the first trial and 50.2% versus 14.3% in the second. Average weight loss on tirzepatide was 17.7% and 19.6%.

Tirzepatide also lowered systolic blood pressure, a blood marker of inflammation (hsCRP), and the time spent with low oxygen levels during sleep. In its approval announcement, the FDA said the improvement in AHI is likely related to the reduction in body weight. There is no evidence that tirzepatide acts on the airway directly.

Two cautions apply. Averages hide the spread: about half or more of participants still had more than mild disease at one year. And the label states that the trials did not evaluate when, or whether, it is appropriate to stop PAP. A repeat sleep study, not the scale, shows whether apnea has resolved.

Side effects and how common they are

The numbers below come from the pooled safety data in the prescribing information for the weight-management tirzepatide product: two placebo-controlled weight-management trials in which 2,519 adults took tirzepatide for up to 72 weeks. The label cautions that rates from one drug's trials cannot be directly compared with rates from another's.

Overall, 56% of people on any dose of tirzepatide reported some gastrointestinal side effect, compared with 30% on placebo. Most were mild to moderate. Severe gastrointestinal reactions were reported in 1.7%, 2.5%, and 3.1% of people on 5 mg, 10 mg, and 15 mg, against 1% on placebo.

Most people stayed on treatment. Side effects led 4.8%, 6.3%, and 6.7% of participants on 5 mg, 10 mg, and 15 mg to stop permanently, compared with 3.4% on placebo, and most of those who stopped did so in the first few months because of gastrointestinal symptoms.

Other effects the label describes

• Hair loss was tied to weight reduction and was far more common in women (7.1%) than in men (0.5%). No one on tirzepatide left the trials because of it.
• Heart rate rose by an average of 1 to 3 beats per minute, with no increase on placebo.
• Gallbladder problems: gallstones in 1.1% versus 1%, gallbladder inflammation in 0.7% versus 0.2%, and gallbladder removal in 0.2% versus none. The label links acute gallbladder events to weight reduction itself.
• Acute kidney injury was reported in 0.5% versus 0.2%. Most cases described in post-approval reports followed dehydration from vomiting or diarrhea.
• Allergic-type reactions, mostly rash and itching, occurred in about 5% versus 3% on placebo. Severe reactions occurred in 0.1%. Anaphylaxis and angioedema have been reported since approval.

The boxed warning and other serious risks

Thyroid C-cell tumors

Tirzepatide carries the FDA's most prominent warning, a boxed warning, for the risk of thyroid C-cell tumors. In a 2-year rat study, tirzepatide caused thyroid C-cell tumors, both benign and cancerous, in a dose-dependent and duration-dependent way, at blood levels comparable to those in people taking the drug. A 6-month study in genetically modified mice did not find tumors.

It is unknown whether tirzepatide causes these tumors, including medullary thyroid carcinoma (MTC), in humans. The label says the human relevance of the rat finding has not been determined. It also says routine monitoring with blood calcitonin tests or thyroid ultrasound is of uncertain value and may lead to unnecessary procedures. Symptoms to report include a lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness.

Who should not use tirzepatide

• Anyone with a personal or family history of medullary thyroid carcinoma.
• Anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), an inherited condition that raises the risk of MTC.
• Anyone who has had a serious allergic reaction to tirzepatide or any ingredient in the product.

Those are the formal contraindications. The label also says tirzepatide is not recommended for people with severe gastroparesis (a stomach that already empties too slowly), should be stopped when pregnancy is recognized, and should be used with caution by anyone who has had angioedema or anaphylaxis with a GLP-1 drug.

Other warnings on the label

• Pancreatitis. Acute pancreatitis, including fatal cases, has been observed with GLP-1 drugs and with tirzepatide. In the pooled weight trials it was confirmed in 0.2% of people on tirzepatide and 0.2% on placebo. In the sleep apnea trials the rate was 0.84 per 100 patient-years on tirzepatide and zero on placebo. The label says to stop the drug if pancreatitis is suspected.
• Dehydration and the kidneys. Prescribers are told to monitor kidney function in anyone with side effects that could cause fluid loss, especially during dose increases.
• Diabetic retinopathy. In people with type 2 diabetes, rapid improvement in blood sugar has been associated with temporary worsening of diabetic eye disease, so those with a history of retinopathy should be monitored.
• Anesthesia and sedation. Because the drug delays stomach emptying, there have been rare reports of people on GLP-1 drugs inhaling stomach contents during general anesthesia or deep sedation despite fasting as instructed. The label says there is not enough data to recommend a specific precaution. It tells patients to inform their healthcare providers before any planned surgery or procedure.

A warning that was removed in 2026

Earlier labels for the weight-management tirzepatide product carried a warning about suicidal thoughts and behavior, language inherited from older weight-loss drugs. On January 13, 2026, the FDA announced that a comprehensive review, including a meta-analysis of 91 placebo-controlled trials with 107,910 participants, found no increased risk with GLP-1 medications, and the warning has since been removed from that label. The FDA still advises reporting new or worsening depression, suicidal thoughts, or unusual mood changes. In the United States, the 988 Suicide and Crisis Lifeline is available by call or text at any hour.

When to seek urgent care

Get medical help right away if you are taking tirzepatide and develop any of the following:

• Severe pain in the upper abdomen that does not go away, with or without vomiting, especially if it spreads to your back (possible pancreatitis).
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools (possible gallbladder disease).
• Swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, a severe rash, or fainting (possible serious allergic reaction).
• Vomiting or diarrhea severe enough that you cannot keep fluids down, or you are urinating very little or feel dizzy when standing (possible dehydration and kidney injury).
• Shakiness, sweating, confusion, or a racing heartbeat, particularly if you also take insulin or a sulfonylurea (possible low blood sugar).

Tirzepatide and birth control pills

This interaction is specific enough to tirzepatide that it deserves its own section, and it is easy to miss. The FDA label for the weight-management tirzepatide product states that the drug may reduce the effectiveness of oral hormonal contraceptives because of delayed stomach emptying.

What the interaction study found

In the manufacturer's drug interaction study, participants took a combined birth control pill (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) after a single 5 mg dose of tirzepatide. Peak blood levels of ethinyl estradiol fell by 59%. Peak levels of norgestimate and of its active form norelgestromin fell by 66% and 55%. Total exposure over time fell less, by 20% to 23%. The pill's hormones also peaked 2.5 to 4.5 hours later than usual.

Why the timing matters

The effect on the stomach is not constant. The label says the delay in emptying is largest after the first dose and diminishes over time. Using acetaminophen as a marker, a first 5 mg dose of tirzepatide cut the peak acetaminophen level by 55%, but by week 6, at 15 mg, there was no meaningful effect. An earlier phase 1 study found the same fading, although some delay was still measurable in participants with type 2 diabetes after several doses.

What the label advises

The label advises people using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation. The label does not spell out the total, but the arithmetic follows from its minimum intervals: if every dose increase on the way to 15 mg were taken after exactly 4 weeks, the backup windows would run back to back for roughly the first 24 weeks.

Contraceptives that do not pass through the stomach, such as an IUD, implant, injection, patch, or vaginal ring, should not be affected, according to the label. The label does not present pregnancy-rate data for pill users on tirzepatide. The advice is a precaution based on hormone levels.

The stakes are real. The label states that weight loss offers no benefit during pregnancy and may harm the fetus, and that tirzepatide should be stopped when pregnancy is recognized. In rats and rabbits, exposure during pregnancy was associated with reduced fetal growth, and in rats with fetal abnormalities. Human data are too limited to estimate the risk.

The same mechanism can affect other oral medicines. The label calls for caution, and for monitoring of drugs with a narrow margin between too little and too much, naming warfarin as an example.

Compounded and unapproved tirzepatide

Compounded drugs are not FDA approved. When the shortage ended, the FDA's grace periods for compounders ran out on February 18, 2025 for state-licensed pharmacies and March 19, 2025 for outsourcing facilities. The agency has said compounders may face enforcement action for making products that are essentially copies of an approved drug, unless a prescriber determines and documents that the compounded product contains a change that makes a significant difference for an individual patient.

As of May 31, 2026, the FDA had received more than 730 reports of adverse events associated with compounded tirzepatide. The agency notes that state-licensed pharmacies that are not outsourcing facilities are not required to report, so the true figure is probably higher, and that a report does not prove the product caused the event.

The specific problems the FDA describes are these: dosing errors with compounded semaglutide injections, including patients measuring the wrong amount and clinicians miscalculating doses, some leading to hospitalization; compounded semaglutide or tirzepatide prescribed at doses above the approved label or escalated faster than the label; fraudulent products labeled with pharmacies that do not exist or did not make them; and products sold online "for research purposes" or "not for human consumption" that may contain the wrong ingredient, too much, too little, or none.

Myths and realities

Myth: GIP is the fat-burning half of the drug

Reality: no human study has shown that the GIP component burns fat or raises metabolism. The clearest measured differences from a GLP-1-only drug in humans are in insulin secretion and insulin sensitivity. The manufacturer's own mechanistic study concluded that energy expenditure and fuel use need further evaluation.

Myth: it works by paralyzing your stomach

Reality: slower stomach emptying is real but fades with repeated dosing, while weight loss continues for months. The label attributes the reduction in calorie intake to effects on appetite, and animal studies show the drug reaching appetite centers in the brain.

Myth: the highest dose is the goal

Reality: the label lists 5 mg, 10 mg, and 15 mg all as maintenance doses for weight reduction. In SURMOUNT-1, going from 10 mg to 15 mg added about 1.4 percentage points of average weight loss. The right dose balances response against tolerability.

Myth: a slow first 12 weeks means it will not work

Reality: 90% of SURMOUNT-1 participants who had lost less than 5% at week 12 passed that mark by week 72 if they stayed on treatment, though their average loss was about half that of early responders.

Myth: once the weight is off, the job is done

Reality: in SURMOUNT-4, people switched to placebo regained 14.0% of their body weight within a year. The label describes the weight-management tirzepatide product as a treatment to reduce weight and to maintain that reduction long term.

How strong is the evidence overall

It helps to sort what you have read into tiers. The weight, blood sugar, sleep apnea, and side-effect numbers come from large phase 3 randomized, double-blind trials with hundreds to thousands of participants, the strongest kind of clinical evidence. The insulin sensitivity and appetite findings come from a single 117-person mechanistic trial. The time-course, plateau, body-composition, and beta-cell analyses are post hoc looks at SURMOUNT-1 data. The explanations for why GIP helps, including reduced nausea and fat-tissue insulin sensitization, rest mainly on animal and cell studies.

Nearly all of this research, including the mechanistic work, was funded by the manufacturer and co-authored by its employees. That is normal for a new drug, and the pivotal trials were reviewed by the FDA, but independent replication of the mechanism studies is thin, and the longest randomized follow-up so far is about three years in people with obesity and a median of about four years (210 weeks) in SURPASS-CVOT.

Questions to ask your doctor

• Do I have any personal or family history, such as medullary thyroid cancer or MEN 2, that rules tirzepatide out?
• Which of my current medications could be affected by slower stomach emptying, and do my insulin, sulfonylurea, or blood pressure doses need to change?
• I use birth control pills. What backup method should I use, and for how long, given my planned dose increases?
• How quickly do you plan to raise my dose, and what would make you hold at a lower dose or step back down?
• How will we protect muscle while I lose weight, and should protein intake and resistance training be part of the plan?
• If I have sleep apnea, when should I repeat a sleep study, and should I keep using PAP in the meantime?
• What is the long-term plan: how long do you expect me to stay on it, and what happens if I need to stop for surgery, pregnancy, or supply reasons?

For background on how this medication fits alongside other options, see the overview of medical weight loss approaches and the tirzepatide treatment page.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.